MK 1084
Alternative Names: MK-1084Latest Information Update: 08 Apr 2024
At a glance
- Originator Merck Sharp & Dohme Corp.
- Class Antineoplastics; Small molecules
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Non-small cell lung cancer
- Phase I Solid tumours
Most Recent Events
- 04 Apr 2024 Phase-III clinical trials in Non-small cell lung cancer (Combination therapy, First-line therapy, Metastatic disease) at unknown location (PO) (NCT06345729)
- 12 Mar 2024 Merck & Co entered into a research collaboration and license agreement with Taiho Pharmaceuticals and Astex Pharmaceuticals to research for the development of MK 1084
- 26 Feb 2024 Updated efficacy and adverse events data from a phase-I trial in Solid tumours presented at the ESMO Targeted Anticancer Therapies Congress 2024 (TAT-2024)